AXSM
Axsome Therapeutics, Inc.
Key Financials
Net Income
$-183174000
↑ 36.2%
Revenue
$638.5M
↑ 65.5%
Operating Income
$-166762000
↑ 40.6%
EPS (Diluted)
$-3.68
↑ 38.6%
Cash & Equivalents
$322.9M
↑ 2.4%
Total Liabilities
$601.5M
↑ 17.6%
Shareholders' Equity
$88.3M
↑ 54.9%
Total Assets
$689.8M
↑ 21.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 4 | 2/27/2026 | View on SEC |
| 144 | 2/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AXSM |
| Company Name | Axsome Therapeutics, Inc. |
| CIK | 1579428 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (212) 332-3241 |